GPVI


Also found in: Medical, Wikipedia.
AcronymDefinition
GPVIGlobal Prospecting Ventures, Inc.
GPVIGenitoanal Papilloma Virus Infection
References in periodicals archive ?
Nieswandt, "Platelet GPVI: a target for antithrombotic therapy?!," Trends in Pharmacological Science, vol.
The GPVI said more than PS1m could be saved by reducing back-office, political and trade union staffing costs and the associated energy and maintenance costs.
GPVI, a major receptor for collagen, is a transmembrane glycoprotein with a molecular weight of 62 kDa.4FcRg is a dimer that forms a high-affinity complex with two molecules of GPVI on the surface of the platelet.24 FcgRIIA (CD32) is another member of the immunoglobulin super family with a molecular weight of 40 kDa.4It exists in close proximity to the GPIb-IX-V complex.
The immunoglobulin superfamily member GPVI and integrin [alpha]2/[beta]l are most notable and essential for collagen-induced platelet activation and aggregation (Farndale et al.
More recently, we reported that the variation in platelet GPVI content directly correlates with platelet prothrombinase activity, suggesting that platelet GPVI levels could represent yet another genetic risk factor for vascular thrombosis or excessive bleeding.
Its biologic drug candidate is based on academic research on a platelet glycoprotein called GPVI, a platelet receptor of collagen and polymerized fibrin.
This interaction slows down the platelets enabling them to interact with the exposed collagen via GPVI and platelet activation to ensue [57-59].
Their targets on platelet membranes include the receptors GPIb-IX-V, [[alpha].sub.II][[beta].sub.3] integrin (GPIIb-IIIa), [[alpha].sub.2][[beta].sub.1] integrin, and GPVI and also their ligands, von Willebrand factor (vWF), fibrinogen, and/or collagen [4, 45].
Glycoprotein VI (GPVI) is a receptor for collagen on platelets and is a protein that is critical for platelet microparticle formation.
This is of special interest especially in the light of a previous study where platelets isolated from "motheaten viable mice", which have a defect in the SHP-1 gene, were hyporesponsive to GPVI stimulation suggesting a physiological role for SHP-1 in lowering the threshold for activation by GPVI [27].
In another study they demonstrate the ability of PPAR-[gamma] ligands to modulate collagen stimulated platelet function and suppress activation of the glycoprotein VI (GPVI) signaling pathway.